Avalo Therapeutics 开始 AVTX-009 治疗化脓性汗腺炎的 2 期 LOTUS 试验。 Avalo Therapeutics begins Phase 2 LOTUS trial of AVTX-009 for treating hidradenitis suppurativa.

Avalo Therapeutics 已启动 2 期 LOTUS 试验，为其首位患者服用 AVTX-009，这是一种靶向白细胞介素-1β 的单克隆抗体，用于治疗化脓性汗腺炎 （HS）。 Avalo Therapeutics has initiated the Phase 2 LOTUS trial, dosing its first patient with AVTX-009, a monoclonal antibody targeting interleukin-1β, for treating hidradenitis suppurativa (HS). 这项研究将涉及180名中度至重度HS的成年人,并将药物的疗效和安全性与安慰剂进行比较. The study will involve 180 adults with moderate to severe HS and will compare the drug's efficacy and safety against a placebo. 预计2026年将取得结果,这标志着在统一制度治疗方面可能取得进展。 Results are anticipated in 2026, marking a potential advancement in HS treatment.